NEXCEDE
LOE ApproachingNDAORALFILM
Approved
Nov 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEXCEDE is an oral film formulation approved by Novartis in 2009 as a small-molecule NDA. The mechanism of action and indication are not publicly detailed in available data. The product is approaching loss of exclusivity, indicating it has matured in the market.
LOE Approaching
Product is in late-stage maturity with moderate competitive pressure (30/100), suggesting smaller brand teams focused on retention and managed care negotiations rather than growth expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NEXCEDE currently has zero linked job openings, reflecting its late-lifecycle stage and approaching loss of exclusivity. Career growth on this product is constrained; professionals seeking advancement should consider rotation to earlier-stage assets or specialty therapeutic areas within Novartis.
Brand ManagerField Sales Representative
Worked on NEXCEDE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.